Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Vivus

Sort by

Implications Stemming From FDA Requirement for Extremely Large Cardiovascular Outcomes Study for Orexigen's Contrave (VVUS, $8.00)

Sunday, June 5, 2011 · 3:44 pm

Read More

For Yearly-Access Subscribers Only

Friday, January 1, 1999 · 4:00 am

Read More

For Monthly-Access Subscribers Only

Friday, January 1, 1999 · 3:00 am

Read More

There are 3 reports on file.

« Back to Company Reports Index